Overview
- The Federal Trade Commission filed a federal complaint on July 29, 2026 accusing Hims & Hers of secretly sending consumers' sensitive medical information to advertising platforms including Meta and Snap and of using hidden tracking pixels and customer‑list matching.
- The FTC also alleges the company broke the Restore Online Shoppers' Confidence Act by charging customers for prescriptions almost immediately after intake and using dark‑pattern interfaces and hard‑to‑find cancellation paths.
- The July 29 disclosure sent Hims shares down about 14.7% in one day, erasing roughly $970 million in market value and prompting Velanki v. Hims & Hers, a securities class action filed in the Northern District of California.
- Multiple plaintiff firms including Robbins Geller, Hagens Berman, and Faruqi & Faruqi are investigating and soliciting investors and whistleblowers, and investors who bought HIMS stock between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead‑plaintiff status.
- If proven, the FTC's claims could bring consumer‑protection fines and reputational damage to Hims while raising broader questions about the use of third‑party ad tracking in telehealth and the risks such practices pose to patient privacy and billing transparency.